A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Clinical Cancer Research|2019Cited by 101
Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshopPooja Hingorani, Damon R. Reed, Katherine A. Janeway et al.|Cancer Genetics|2016Cited by 52
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly Pacenta, Theodore W. Laetsch, Wendy Allen‐Rhoades et al.|Journal of Clinical Medicine|2021Cited by 28
Table S5 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Table S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0